公开(公告)号：US20240360087A1

公开(公告)日：2024-10-31

申请号：US18577880

申请日：2022-07-11

Applicant: SCANDION ONCOLOGY A/S

Inventor： Kaare G. RASMUSSEN ,  René EGEBRO ,  Klaus Snej JENSEN ,  Kiara LOBATO ,  Lorraine SHARP

IPC: C07D257/04 ,  A61K45/06

CPC classification number: C07D257/04 ,  A61K45/06

Abstract: The present invention relates to an improved crystal form of SCO-101, its preparation and use. Further, the invention relates to intermediary crystal forms of SCO-101 that can be converted to the improved crystal form of SCO-101.

公开(公告)号：US20210353596A1

公开(公告)日：2021-11-18

申请号：US17388208

申请日：2021-07-29

Applicant: Scandion Oncology A/S

Inventor： Nils Aage Brünner ,  Palle Christophersen ,  Jan Stenvang ,  Jens Lichtenberg ,  Annemette Thougaard

IPC: A61K31/41 ,  A61P35/00 ,  A61K33/243 ,  A61K31/138 ,  A61K31/337 ,  A61K31/495 ,  A61K31/513 ,  A61K31/566 ,  A61K31/4745 ,  C07D257/04

Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

公开(公告)号：US20240374567A1

公开(公告)日：2024-11-14

申请号：US18569256

申请日：2022-06-14

Applicant: Scandion Oncology A/S

Inventor： Peter Michael Vestlev ,  Nicklas Lindland Roest

IPC: A61K31/41 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K38/19

Abstract: The present invention relates to treatment of subgroups of cancer patients, methods for identifying treatment and dosage regimens, as well as methods for identifying these subgroups of cancer patients.

公开(公告)号：US20240277666A1

公开(公告)日：2024-08-22

申请号：US18569263

申请日：2022-06-14

Applicant: Scandion Oncology A/S

Inventor： Peter Michael Vestlev ,  Nicklas Lindland Roest

IPC: A61K31/41 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00 ,  G01N33/72

CPC classification number: A61K31/41 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00 ,  G01N33/728 ,  G01N2800/52

Abstract: The present invention relates to treatment of subgroups of cancer patients, methods for identifying treatment and dosage regimens, as well as methods for identifying these subgroups of cancer patients.

公开(公告)号：US11103481B2

公开(公告)日：2021-08-31

申请号：US16302195

申请日：2017-05-17

Applicant: Scandion Oncology A/S

Inventor： Nils Aage Brünner ,  Palle Christophersen ,  Jan Stenvang ,  Jens Lichtenberg ,  Annemette Thougaard

IPC: A61K31/41 ,  A61P35/00 ,  A61K33/243 ,  A61K31/138 ,  A61K31/337 ,  A61K31/495 ,  A61K31/513 ,  A61K31/566 ,  A61K31/4745 ,  C07D257/04

Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

公开(公告)号：US11903927B2

公开(公告)日：2024-02-20

申请号：US17388208

申请日：2021-07-29

Applicant: Scandion Oncology A/S

Inventor： Nils Aage Brünner ,  Palle Christophersen ,  Jan Stenvang ,  Jens Lichtenberg ,  Annemette Thougaard

IPC: A61K31/41 ,  A61P35/00 ,  A61K33/243 ,  A61K31/138 ,  A61K31/337 ,  A61K31/495 ,  A61K31/513 ,  A61K31/566 ,  A61K31/4745 ,  C07D257/04

CPC classification number: A61K31/41 ,  A61K31/138 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/566 ,  A61K33/243 ,  A61P35/00 ,  C07D257/04 ,  A61K31/41 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00

Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

公开(公告)号：US20210251963A1

公开(公告)日：2021-08-19

申请号：US17272808

申请日：2019-09-06

Applicant: Scandion Oncology A/S

Inventor： Nils Aage Brünner ,  Jan Stenvang

IPC: A61K31/41 ,  A61K31/573 ,  A61K31/565 ,  A61K31/138 ,  A61K45/06 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/337 ,  A61P35/00

Abstract: The present invention relates to treatment of diseases characterized by elevated expression and/or activity of SRPK1 with specific SRPK1 inhibitors and to methods for identifying subjects who may benefit from such treatment.

公开(公告)号：US10975079B2

公开(公告)日：2021-04-13

申请号：US15555152

申请日：2016-02-24

Applicant: SCANDION ONCOLOGY A/S

Inventor： Steffen Rump ,  Henning Weigt

IPC: A61K31/15 ,  A61K31/519 ,  A61K31/565 ,  A61K31/566 ,  A61K31/5685 ,  A61K45/06 ,  C07D487/04 ,  A61K31/015

Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or propharmacons thereof for use as BCRP inhibitors, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant σp greater than 0.23. For corresponding compounds, surprisingly a particularly high inhibitory activity against BCRP has been discovered which can be exploited for suppressing the multidrug resistance modulator BCRP, thus providing an improvement in efficacy of BCRP affected drugs. This has useful implications for cancer and HIV treatment.

公开(公告)号：US20180044341A1

公开(公告)日：2018-02-15

申请号：US15555152

申请日：2016-02-24

Applicant: SCANDION ONCOLOGY A/S

Inventor： Steffen RUMP ,  Henning WEIGT

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/015 ,  A61K31/519 ,  A61K31/565 ,  A61K31/566 ,  A61K31/5685 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or propharmacons thereof for use as BCRP inhibitors, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant σp greater than 0.23. For corresponding compounds, surprisingly a particularly high inhibitory activity against BCRP has been discovered which can be exploited for suppressing the multidrug resistance modulator BCRP, thus providing an improvement in efficacy of BCRP affected drugs. This has useful implications for cancer and HIV treatment.